drugset
drugset / Trial / NCT06464861

Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma

NCT06464861 ↗

Phase 1 Recruiting 52 enrolled Second Affiliated Hospital, School of Medicine, Zhejiang University
NaSingle-groupOpen-labelTreatment

Summary

To study the safety and efficacy of cord blood-derived CD19 CAR-NK cells sequential with 7x19 CAR-T in relapse / refractory B cell lymphoma

Timeline

Start
2024-06-20
Primary completion
2026-06-30
Completion
2027-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject 7x19 CAR-T Cell therapy 2e+06 cells/kg —
Subject anti-CD19 CAR-NK Cell therapy 2e+06 cells/kg Intravenous

Indications

mantle cell lymphoma primary mediastinal large B-cell lymphoma